Crude Oil Down 2%; Citigroup Profit Tops Estimates
Portfolio Pulse from Lisa Levin
US stocks traded higher with Dow Jones gaining over 100 points. Citigroup reported better-than-expected Q2 results with a net revenue of $19.44 billion, beating the consensus of $19.27 billion. Aehr Test Systems, Frequency Therapeutics, and ACADIA Pharmaceuticals saw their shares rise after positive news, while Theseus Pharmaceuticals, Galmed Pharmaceuticals, and Leslie's saw their shares drop due to negative developments. Crude oil traded down 2%.
July 14, 2023 | 4:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ACADIA Pharmaceuticals shares rose after acquiring rights to certain drugs and announcing guidance.
Acquisition news and positive guidance typically have a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Aehr Test Systems shares rose after reporting better-than-expected Q4 results and strong guidance.
Positive earnings and strong guidance typically have a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Citigroup reported better-than-expected Q2 results.
Better-than-expected earnings typically have a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Frequency Therapeutics shares rose after agreeing to merge with Korro Bio.
Merger news typically have a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Galmed Pharmaceuticals shares dropped after announcing pricing of a public offering.
Public offering pricing news typically have a negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Leslie's shares dropped after releasing preliminary Q3 results and announcing a CFO transition.
Negative earnings news and executive transitions typically have a negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Theseus Pharmaceuticals shares dropped after discontinuing enrollment in a study and terminating development of a drug.
Negative drug development news typically have a negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100